Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BMB-101

Other · developed by Bright Minds Biosciences Pty

Phase 2 Most advanced trial
DRUG Developer
1 Registered trials

What is BMB-101?

BMB-101 is an investigational drug studied in Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Bright Minds Biosciences Pty Ltd (DRUG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06401538 Phase 2 Absence Epilepsy Recruiting DRUG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Absence EpilepsyDravet SyndromeJeavons SyndromeLennox Gastaut Syndrome

More from Bright Minds Biosciences Pty

BC-101 Phase 1 BPT567 Phase 1 YB-1113 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the DRUG page.

Follow DRUG, the company behind BMB-101

See DRUG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DRUG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.